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Triple negative breast cancer represents a strong clinical challenge due to its high 
invasiveness and the lack of therapeutic targets. To overcome this problem, recent 
combination therapeutic strategies have been implemented. When treated during early 
phases, a combination of surgery, chemotherapy, and irradiation therapy is usually 
performed, which significantly improves the overall survival of the patients. However, when 
detected later, triple negative breast cancer begins to metastasize, considerably reducing the 
effectiveness of the treatments. As a potential solution to this problem, we propose a novel 
treatment of metastatic triple negative breast cancer that combines targeted photothermal 
therapy with a checkpoint inhibitor treatment. Photothermal therapy is a recent irradiation 
therapy based on the electromagnetic radiation of photosensitizers. When exposed to 
specific electromagnetic radiation, photosensitizers absorb irradiating energy and releases it 
as heat to the surrounding environment. The resulting heat can be used to disrupt the 
membranes of cancer cells or to denature essential cytoplasmic proteins, inducing tumor 
elimination. This approach is interesting because it can induce the release of tumor antigens 
and proinflammatory cytokines that can be used to treat metastases.  
The effectiveness of a novel targeted conjugate for targeted photothermal therapy based on 
single-walled carbon nanoparticles was assessed in vitro, and the ability of the treatment to 
release proinflammatory cytokines in mice was demonstrated. This new treatment showed 
significant cytotoxicity against EMT6 triple negative breast cancer cells, while not affecting 
the cell viability of a healthy endothelial cell model in vitro. In a mouse model, the treatment 
has shown to be effective in releasing cytokines TNFα, IFNγ and IL-6 into the bloodstream 
of the mice. By combination with the checkpoint inhibitor anti-CTLA-4, this approach has 
shown promising results in the treatment of triple negative breast cancer metastases in mice. 
 
1 
Chapter 1: Introduction 
 
1.1. Cancer and treatment strategies 
 
Cancer is a broad group of pathologies occurring in a large number of animal species[1-5]. 
Cancer can be described as an abnormal cell growth, starting in an organ and gradually 
invaded by the tumor cells. At advanced stages, cancer can potentially spread to other 
parts of the body [6-8]. Briefly, cancer stages can be separated in five categories. The first 
one is Stage 0; at this stage the tumor is still located at the initial abnormal division site, 
and cancer does not start to spread to surrounding tissues [9]. At Stage I, also called early-
stage cancer, tumor cells will start to invade nearby tissues [9]. The tumor size is still small 
(generally less than 2 cm), and the cancer cells have not spread yet to the neighboring 
lymph nodes. Stage II and Stage III cancers correspond to larger tumors (generally 2 cm 
to 5 cm for Stage II, and more than 5 cm for stage III), and lymph nodes may be invaded 
by cancer cells at these stages [9]. Stage IV, also called metastatic or advanced stage, 
corresponds to large tumor spreading to other organs and body parts [9].  
 
1.1.1. Triple negative breast cancer 
Triple negative breast cancer (TNBC) is a highly aggressive sub-type of breast cancer, 
and it has been reported to occur in 15% to 20% of the total breast cancer cases [10]. Triple 
negative breast cancers do not express the progesterone receptor, estrogen receptor or 
HER-2 genes [11]. These receptors are usually used to target breast cancer and to treat 
them via endocrine therapy [12]. For this reason, endocrine therapy is ineffective on 
TNBC, and TNBC currently represent a strong clinical challenge due to the lack of 
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existing efficient targeted treatments [12]. This lack of receptors also makes the 
development of new targeted therapies more difficult. TNBC tumors are highly invasive 
and metastatic. They present a poorer prognosis over a period of 5 years post-diagnosis 
when compared to estrogen-positive breast cancers [13-15].  
 
1.1.2. Current treatments for triple negative breast cancer 
Triple negative breast cancer is generally detected and diagnosed at stage II or early III, 
leaving the opportunity of resorting to surgery or radiation therapy as a treatment [16-18]. 
Patients with TNBC are usually treated with a combination of surgery and 
chemotherapy[19] . Among the chemotherapies that can be used to treat TNBC there are: 
• Anthracyclines (such as doxorubicin or idarubicin). These molecules intercalate 
in the DNA of tumor cells and induce a local change in the structure of the DNA 
strand, thereby inhibiting replication processes. Furthermore, anthracyclines are 
inhibitors of type II DNA topoisomerases, enzymes involved in the DNA 
replication and transcription [20].  
• The alkylating agents (such as cyclophosphamide or chlormethine). These 
molecules interact with the purines of the DNA and add alkyl groups to them. 
Cancer cells have a very rapid metabolism. Their proliferation is faster than 
healthy cells, and the mechanisms for controlling and correcting DNA replication 
errors are altered. For these reasons, cancer cells are more susceptible to DNA 
damage, including alkylation[21]. 
• The taxanes (such as paclitaxel or docetaxel). These molecules target β tubulin 
and disrupt the function of the microtubules. β tubulin are responsible for the 
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spindle apparatus and chromosome migration during cell migration. By inhibiting 
β tubulin, the taxanes inhibit cancer cells division[22]. 
In addition to chemotherapy, TNBC patients are also treated with surgery and radiation 
therapy [19]. Patients treated with radiation therapy in addition to chemotherapy and 
surgery shows a lower risk of new tumor development on a treated site (locoregional 
recurrence), and an improved overall survival [23-25]. Radiation therapy is a key asset in 
combinatorial treatments of triple negative breast cancer, and a promising field to be 
explored to improve current TNBC treatments. However, when cancer is detected at later 
stages, metastases may start to develop, making irradiation therapy less effective. In this 
thesis, we explore the use of a recent form of irradiation therapy, photothermal therapy, 
which could be used in the treatment of TNBC metastases. 
 
1.2. Photothermal therapy 
 
1.2.1. Principles of photothermal therapy 
 
Photothermal therapy (PTT) is a form of radiation therapy using electromagnetic 
radiation. Molecules able to absorb electromagnetic radiation, called photosensitizers, can 
be irradiated by a photon beam, and enter transition to an excited state [26]. The energy 
accumulated by the photosensitizers is then released to the nearby environment in the 
form of heat [26]. Nanoparticles are commonly used as photosensitizers, and nanoparticles 
such as carbon nanotubes [27,28], gold nanorods [29,30] or silica-based nanoparticles [31,32] 
have for example been tested for photothermal therapy in the treatment of cancer. The 
heat generated during PTT is due to vibrations of the nanoparticle on a molecular level 
after being exposed to electromagnetic radiation [33]. It has been shown that the heat 
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resulting from PTT is sufficient to eliminate cancer cells via necrosis by rupture of the 
cell membranes, or via hyperthermia by denaturation of cytoplasmic proteins [34,35]. 
Necrosis occurs at temperature above 47°C[36,37].  
 
1.2.2. Carbon nanotubes 
Carbon nanotubes are tubes composed only of carbon atoms with a diameter of a few 
nanometers. Carbon nanotubes can be classified into two categories: single-walled carbon 
nanotubes (SWCNTs) and multi-walled carbon nanotubes (MWCNTs) [38]. Although they 
are not synthesized like that, we can represent the SWNTs as a series of carbon hexagons 
coiled to form a tube. The MWCNTs correspond to SWCNTs nested within each other 
and linked together by weak bounds [39]. A representation is shown in Figure 1. 
 
Figure 1: Single-walled and multi-walled carbon nanotubes representation [40]. 
Single walled carbon nanotubes are represented on the left, and multi-walled carbon 
nanotubes appears as nested SWNTs on the right. 
 
SWCNTs present a high stability and are much less toxic to cells than MWCNTs [41-43]; 
for these reasons SWCNTs are used for photothermal therapy over MWCNTs in this 
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study. Moreover, the average external diameter of SWCNTs is shorter than the diameter 
of MWCNTs, facilitating its transport in the bloodstream for potential in vivo studies. 
 
1.3. Carbon nanotube conjugation for a targeted photothermal therapy 
 
Nanotube carbons being inert, they must be conjugated to a targeting agent in order to 
be able to carry out targeted photothermal therapy. 
 
1.3.1. Phosphatidylserine and triple negative breast cancer targeting 
 
Phosphatidylserine is phospholipid involved in the apoptosis pathway and that can be 
used to detect apoptotic cells in an injured tissue [44,45]. In healthy cells, 
phosphatidylserines are found in the inner layer of the cell membrane [46]. 
Phosphatidylserine (PS) is externalized on the outer layer of the plasma membrane and 
serves notably as a signal for cell death in apoptotic cells [47]. Most cancer cells have been 
shown to express the PS on the outer layer of their cell membrane [48]. This mechanism is 
used by cancer cells to trick the immune system into masquerading as apoptotic cells. 
This PS externalization is also found in TNBC and can be used as a target for targeted 
photothermal therapy [49]. 
 
1.3.2. Annexin V and targeted photothermal therapy 
 
Annexin V (anx V) is a protein whose complete functions are still unknown today. 
However, this protein is commonly used in flow cytometry for its properties to label 
apoptotic cells [44,45]. 
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It has been shown that anx V is capable of fixing the PS externalized by apoptotic 
cells[43,44]. Likewise, annexin V can be used to bind the PS externalized by cancer cells. 
Human annexin V is composed of 320 amino acids. The complete sequence is shown in 
Figure 2: 
 
Annexin has in its sequence a cysteine whose sulfhydryl group will be used for its 
conjugation. The approach used in this thesis consists in conjugating SWNCTs with 
annexin V in order to create a photosensitizer targeted to triple negative breast cancer 
cells. The conjugate will bind to the PS externalized by cancer cells thanks to annexin V. 
The conjugation between carbon nanotubes and annexin V will be done through a linker: 
the1,2-distearoyl-sn-glycero-3-phospho ethanolamine-N-maleimide (polyethylene 








Figure 2: Human annexin V amino acids sequence [49]. This image shows the amino 
acids sequence of human annexin V, each letter corresponding to an amino acid. The 




Figure 3: Structural formula of the 1,2-distearoyl-sn-glycero-3-phospho 
ethanolamine-N-maleimide(polyethylene glycol) linker [50]. The structure contains 
two aliphatic tail (A), a polyethylene glycol molecule (B), and a maleimide molecule 
(C). 
 
The DSPE-PEG-MAL linker has in its structure a maleimide molecule which can react 
with the sulfhydryl groups of cysteines to form a thioether. This property will be used 
later to conjugate annexin V to the linker. SWCNTs are only composed of carbon atoms 
and are therefore very hydrophobic. The linker has long hydrophobic aliphatic tails 
capable of attaching to nanotube carbons. In addition to the targeted aspect, the 
conjugation between SWCNTs and Annexin V improves the solubility of nanotubes. The 
DSPE-PEG-MAL linker also has a polyethylene glycol molecule in its structure which 
reduces the immunogenicity and antigenicity of the conjugate.  
 
1.3.3. Combining checkpoint inhibitors and photothermal therapy 
 
Upon exposure to a pathogen, an initial immune response occurs: the cell-mediated 
immunity. This immune response involves the activation of phagocytes capable of 
eliminating pathogens by phagocytosis mechanisms. This immune response also involves 
the activity of T lymphocytes, which can be classified into different categories: 
• Cytotoxic CD8+ T cells: Once activated by contact with class I MHC-antigen 
complexes, these cells release perforin onto the pathogen. Perforin is a protein 
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capable of inserting into the membrane of targeted pathogens to form holes. The 
pathogen's membrane is disrupted, and the pathogen is eliminated. 
• Helper CD4+ T cells: These cells are activated by antigen presenting cells. The 
main functions of the Helper CD4+ T cells are the activation of cytotoxic T cells 
and macrophages, as well as the release of proinflammatory cytokines. One of 
the main cytokines released is interferon gamma (IFNγ), which activates 
macrophages. Interferon gamma is also produced by the cytotoxic T cells. 
• Regulatory CD4+ T cells: In adults, T lymphocytes are produced in the bone 
marrow and matured in the thymus where they undergo selection to avoid 
autoimmune phenomena. The role of the regulatory T cells is to eliminate 
autoimmune T cells that have escaped selection in the thymus, and to regulate the 
cell-mediated immune response. 
After a first encounter with a pathogen, a second immunity occurs: the humoral immunity. 
In brief, this immunity is characterized by the production of antibodies by B lymphocytes. 
The B lymphocytes are able to internalize antigens and to present them on the surface of 
their membrane via their class II MHC. The complex class II MHC-antigen binds to the 
helper CD4+ T cells, inducing B lymphocyte proliferation. During a future encounter 
with the same antigen, these B lymphocytes cells produce a large number of antibodies 
targeting this antigen. Immune response mechanisms are regulated by immune 
checkpoints whose role is to prevent autoimmune responses. However, these immune 
checkpoints can be exploited by cancer cells to avoid being eliminated by the immune 
system. One of these checkpoints is the protein receptor CTLA-4 or cytotoxic T-
lymphocyte-associated protein 4. The ligands for CTLA-4 are the cluster differentiation 
(CD) 80 and 86, present on the surface of antigen presenting cells. Regulatory CD4+ T 
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cells constitutively express CTLA-4 on their surface, and a CTLA-4 binding to CD80 or 
CD86 induces the lymphocyte inactivation. This mechanism is abused by cancer cells 
which induce the expression of CTLA-4 on the surface of other types of T lymphocytes 
in order to inhibit their activity. To overcome this problem, an antibody targeting CTLA4 
(anti-CTLA-4) can be used. Anti-CTLA-4 binds to CTLA4 and prevents its interaction 
with CD80 or CD86. Our approach is to combine anti-CTLA-4 with photothermal 
therapy, as illustrated in Figure 4: 
 
Figure 4: Mechanisms of anti‐tumor immune response induced by anti-CTLA-4 
treatment combined to photothermal therapy [51]. Photothermal therapy eliminate 
the primary tumor and induces the release of tumor antigens which are internalized by 
antigen presenting cells. Anti-CTLA 4 blocks the CTLA-4 of the regulatory T cells and 
prevents the regulation of the immune response. The antigen presenting cells then 
activate the cytotoxic and helper T cells, inducing a cell-mediated immune response 
against the metastases. The helper T cells activate B lymphocytes proliferation, and 




Photothermal therapy of a primary tumor induces the release of tumor antigens which can 
induce an immune response. Anti-CTLA-4 helps prevent the immune response from 
being regulated. The induced immune response participates in the elimination of other 
tumors distant from the irradiation site, this mechanism is called the abscopal effect. 
 
1.4. Scope of Study 
Hypothesis: 
An SWCNT-anx V conjugate for PTT can specifically target cancer cells and be activated 
via near infrared lights to induce a photothermal effect. The heat generated by the 
conjugate is sufficient to induce a cell death and can be used to treat triple negative breast 
cancer models in vitro and in vivo. 
 
Aim 1: Photothermal therapy studies on a triple negative breast cancer model in vitro:  
The objectives are (1) to treat EMT6 cells with the SWCNT-anx V conjugate combined 
with laser irradiation and measure the tumor temperature elevation and cytotoxicity post 
treatment at room temperature, (2) to treat EMT6 cells at 37°C, to assess the post 
treatment cytotoxicity, and verify the specificity of the conjugate using non-targeted 
SWCNTs as a control, and (3) to assess the effect of treatment on the viability of healthy 
endothelial HUVEC cells. 
 
Aim 2: Photothermal therapy studies on a triple negative breast cancer model in vivo: 
The objectives are (1) to compare intravenous and intratumoral injections of SWCNT-
anx V combined with photothermal therapy for their ability to release proinflammatory 
 
11 
cytokines, (2) to determine the release of proinflammatory cytokines as a function of time 
in mice at various tumor temperatures, and (3) to combine SWCNT-anx V photothermal 
therapy with anti-CTLA-4 treatment and to quantify the release of proinflammatory 
cytokines into the bloodstream of the mice. 




pET-30 Ek/LIC plasmid was constructed and sequenced by EMD Chemicals (Billerica, 
MA). Alamar Blue reagent, isopropyl β-D-1-thiogalactopyranoside (IPTG), tosyl 
phenylalanyl chloromethyl ketone (TPCK), phenylmethylsulfonyl fluoride (PMSF), 
ethylenediaminetetraacetic acid (EDTA) were purchased from Sigma-Aldrich (St Louis, 
MO). HRV-C3 protease was purchased from Sino Biologics (Portland, OR). Dialysis 
membranes (2kDA, 14kDa and 100kDa) were purchased from Spectrum Laboratories 
(Rancho Dominguez, CA). Murine triple negative breast cancer cells EMT6 (ATCC® 
CRL-2755™), human umbilical vein endothelial cells HUVEC (ATCC® CRL-1730™), 
Waymouth's MB 752/1 medium, and vascular cell basal medium were purchased from 
ATCC (Manassas, VA). Fetal bovine serum (FBS) was purchased from Atlanta 
Biologicals (Lawrenceville, GA). Penicillin and streptomycin for cell culture were 
purchased from Invitrogen (Grand Island, NY). HisTrap HP His tag protein purification 
columns were purchased from GE Healthcare Chicago, IL). Ethanol HPLC grade was 
purchased from Acros Organics (Waltham, MA). Yeast extract, tryptone, and kanamycin 
for bacterial culture were purchased from Alfa Aesar (Haverville, MA). DSPE-PEG-
Maleimide linker (PG2-DSML-2k) was purchased from Nanocs (New York, NY). 
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Bradford reagent was purachased from BioRad (Hercules, CA). Anti-CTLA-4 mouse 
monoclonal antibody (clone: 9H10) and mouse IL-6, IL-12, TNFα, IFNγ ELISA kits were 
purchased from Biolegend (San Diego, CA). SWCNTs were obtained from CHASM 
(Boston, MA). Female 6 weeks old BALB/cJ mice were from Jackson Laboratory (Bar 




2.2.1. Annexin V production 
 
E. coli BL21(DE3) was previously transformed with a plasmid ANXA5, pET-30 
Ek/LIC/ANX encoding annexin V marked with a polyhistidine-tag (His-tag) and 
containing a kanamycin resistance gene. The gene coding for the His-tag-marked annexin 
V is also regulated by a Lac regulatory construct. In the presence of IPTG, this gene is 
activated, and recombinant annexin V is produced. First, transformed E. coli BL21(DE3) 
are cultivated in 10 mL of LB media containing 35 µg/mL of kanamycin at 37°C, 200 
rpm shaking and for 12 hours for initial culture. The 10 mL of initial culture are then 
transferred in 1 L of LB media containing 35 µg/mL of kanamycin. The 1 L culture is 
spread into four Erlenmeyer flasks containing 250 mL of seeded medium each, and 
incubated for bacterial growth at 37°C, 200 rpm shaking. Each hour, the optical density 
of the media is measured at 600 nm using a spectrophotometer. Once the optical density 
at 600 nm reached 0.5, 0.4 mM of IPTG is added to each 250 mL Erlenmeyer flask of 
culture for the induction. Induction is performed at 30°C, 180 rpm shaking for 5 hours. 
The recombinant annexin V is produced intracellularly and needs to be extracted and 
purified from the other proteins and contaminants. Bacteria are harvested by 
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centrifugation at 1000g, 4°C, for 10 minutes. Supernatant is discarded, and the pellet is 
resuspended in a sonication buffer containing 1% ethanol, 0.05 mM of TPCK, 1 mM of 
PMSF and 0.02 M of sodium phosphate dibasic. The 4°C temperature, and the TPCK and 
PMSF (both proteases inhibitors) ensure the stability and the protection of the 
recombinant annexin V. β-mercaptoethanol (0.01%) is also added to the sonication buffer 
to prevent protein oxidation. Once fully resuspended in the sonication buffer, the cells are 
sonicated at 4°C for 30 seconds and 4.5 watts, then 30 seconds of pause, to break the cells 
membranes and release the intracellular proteins. This cycle was repeated four times. 
Soluble and non-soluble proteins and cell wastes are then separated by centrifugation 
during 30 minutes, at 12,000g and 4°C. The pellet is discarded and 40 mM of imidazole 
and 500 mM of NaCl is added to the supernatant. The annexin V is then purified via a 
nickel chromatography column. The polyhistidine-tag attached to the recombinant 
annexin V is trapped within the column by interacting with the Ni-NTA resin. Imidazole 
and NaCl are added to the supernatant to reduce unspecific binding. Annexin V is then 
eluted by feeding a buffer containing high concentration of imidazole (500 mM) through 
the column. The flowthrough is collected, and the polyhstidine-tag is then cleaved by a 
HRV3C protease (10U/mg of protein). A complete protocol is available in Appendix A. 
The amount of protein produced is then determined with a Bradford Assay. In the 
presence of protein, the Bradford assay reagent forms a complex with a high 595 nm 
absorbance. This absorbance is measured by a spectrophotometer and is proportional to 
the amount of protein in the sample. For each samples of annexin V produced, 5 µL were 
added to 96 wells containing 250 µL of Bradford reagent. The absorbance is then read 




2.2.2. SWCNT-annexin V conjugation 
SWCNTs (6 mg) were solubilized in 5 mL of 1% SDS. The solubilized SWCNTs were 
sonicated for 30 minutes at 6.5 watts and then centrifugated at 14,000g for 30 minutes. 
This cycle was repeated four times. DSPE-PEG-MAL linker (1.5 mg) solubilized in 1 mL 
of 1% SDS was then added, and the suspension was slowly stirred for 30 minutes at room 
temperature. During this step, hydrophobic interactions occurs between the SWCNTs and 
the DSPE functional groups of the linker. The SWCNT-linker suspension was then 
dialyzed for 8 hours against 2 L of DI water using a 2kDa dialysis membrane to remove 
unconjugated linkers and excess SDS. Annexin V (1 mL at 5mg/mL) was added to 2 mL 
of the SWCNT-linker suspension and slowly agitated for 2 hours at room temperature. 
Annexin V has one cysteine in its amino acid sequence. During this step, the sulfhydryl 
group of the cysteine reacts with the maleimide of the linker to form a thioether bond. 
This reaction is shown in Figure 5:  
 
Figure 5: Maleimide conjugation reaction to a sulfhydryl group [52]. The maleimide 
of the DSPE-PEG-MAL linker reacts with the sulfhydryl group of the cysteine of the 
annexin V to form an irreversible thioether bond at a pH of 6.5 to 7.5. 
 
The unreacted sites on the linkers were blocked by adding 0.166 mg of L-cysteine and 
slowly shaking for 1 hour at room temperature. The SWNCT-anx V suspension was 
dialyzed against 2 L of 20 mM sodium phosphate buffer at pH 7.4 during 8 hours at 4°C 
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using a 100 kDa dialysis membrane to remove unconjugated annexin V and excess L-
cysteine. As a last step, the SWNCT-anx V suspension was centrifuged at 14,000g for 1 
hour to remove the aggregates.  
2.2.3. Cell culture 
EMT6 cells were grown in Waymouth’s MB 752/1 medium with 2 mM L-glutamine 
complemented with 15% FBS, penicillin (100 U/mL) and streptomycin 100 μg/mL. Cell 
growth was performed inside of an incubator at 37°C, 5% CO2. EMT6 cells are highly 
invasive mice triple negative breast cancer cells frequently used for in vivo studies in 
mice. Their ability to metastasize quickly makes these cells a relevant model for our 
study. In addition, as our conjugate will be injected intravenously, human umbilical vein 
endothelial cells (HUVEC) was used as a control to assess the effect of the treatment on 
healthy cells. 
2.2.4. In vitro SWCNT-annexin V based photothermal therapy 
EMT6 cells were seeded in 24 well plates at a density of 20,000 cells per well. One well 
out of two was left empty to limit heat transfer between wells and to make sure the 
temperature measurements of a well will be independent from the measurement of the 
next one. After 48 hours, the media in each well was replaced with fresh media containing 
2 mM of CaCl2 and UV-sterilized SWNT-anx V conjugate and incubated at 37°C, 5% 
CO2 for 2 hours. During this incubation period, the conjugate binds to phosphatidylserine 
exposed on the surface of the cancer cells. After the incubation period, the media is 
removed, and each well is washed with 300 µL of PBS. This washing step is repeated 
four times to remove the excess SWNT-anx V not bound to the cells. Cells were then 
irradiated with a Diodevet-50 NIR laser at 980 nm. The power density used was 1 W/cm². 
Depending on the experiment, the irradiation was performed at room temperature, or 
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inside of an incubator at 37°C to mimic physiological temperatures. Right after the 
experiment, the media is removed under a biosafety hood in sterile conditions and 
replaced with 250 µL of fresh media containing 10% AlamarBlue. The AlamarBlue 
reagent is a non-toxic dye also called resazurin. Resazurin is irreversibly reduced to a 
pink, fluorecent compound in proportion to aeorbic respiration. The cells are incubated 
for 1 to 4 hours at 37°C, 5% CO2 until the color of the media of the control wells turned 
pink. The media in each wells was transferred to an opaque, black, 96 well plate and the 
fluorescence of each wells was measured (excitation at 530 nm and emission at 590 nm). 
The fluorescence of the control is used to normalize the results (average absorbance of 
the controls wells is set at 100% viability) and the relative viability in each well is 
calculated. The viability assay is performed in sterile conditions, which does not allow a 
thermocouple to be present in the well. For this reason, in a separate experiment, at the 
end of the irradiation of each wells, the cap of the plate is removed and the temperature 
at the bottom of the well is measured using a type j surface thermocouple.  
 
2.2.5. In vivo SWCNT-annexin V based photothermal therapy 
All the in vivo experiments described in this section were approved by the by Institutional 
Animal Care and Use Committee (IACUC) of the University of Oklahoma, and were 
performed by a staff with proper veterinarian training. Female 6 weeks old BALB/cJ mice 
were used as a model. Tumor induction was performed by orthotopic injection of 106 
EMT6 cells in 100 µl of PBS in the fourth mammary fat pat. After 12 days post tumor 
induction, mice received intravenous injections of SWCNT-annexin V (1.2 mg of 
conjugate per kg of body mass) in the lateral tail vein. In a separate experiment, mice 
were also injected intratumorally to compare the effects of intratumoral and intravenous 
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injections. Mice were then treated with an NIR laser 3 hours after the SWCNT-anx V 
conjugate injection. A region with a diameter corresponding to the diameter of the tumor 
+ 5 mm was treated. The laser wavelength was 980 nm, the power level was 1 W/cm² and 
the irradiation time was 175 seconds. Tumor temperature was monitored during the 
irradiation using a FLIR I7 thermal camera. During the irradiation, mice were 
anesthetized with 98% oxygen / 2% isoflurane via a nose cone. Seven days post 
photothermal therapy, the mice were euthanized via CO2 with a nose cone followed by a 
bilateral thoracotomy. Following bilateral thoracotomy, blood was collected via intra-
cardiac puncture using a 3 mL syringe. Thirty minutes post blood collection, the blood 
was centrifugated for 15 minutes at 14,000g, the serum was then collected and stored at 
4°C.  
2.2.5. In vivo SWCNT-annexin V based photothermal therapy 
Statistically significance differences of cell viability and cytokine concentration were 
assessed using a one-way ANOVA and Tukey-Kramer multiple comparisons test with 
RStudio software or GraphPad Prism software version 9.0. 
Chapter 3: Results 
 
3.1. SWCNT-annexin V conjugate and properties: 
 
Recombinant annexin V with a molecular weight of 36.5 KDa was produced in E. coli 
and purified with nickel chromatography columns. The annexin V / SWCNT ratio of the 
conjugate was determined by spectrophotometry. The concentration of annexin V was 
determined by measuring the absorbance of the conjugate after a Bradford assay at 595 
nm, and the concentration of SWCNT was determined by measuring the absorbance of 
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the conjugate at 800 nm. As a control, absorbance at 595 nm of a DSPE-PEG-MAL 
linker-SWCNT conjugate (without annexin V) was measured and shown that the 
conjugate does not absorb at 595 nm in absence of annexin V. Absorbance at 800 nm of 
unconjugated annexin V was also measured to show that annexin V does not absorb at 
800 nm. The average annexin V / SWCNT ratio of the different batches of conjugates 
used for the in vitro experiments presented in this thesis was 28.7 (with a minimum ratio 
of 22.1 and a maximum ratio of 35.4).  
The photothermal effect of the SWCNT-anx V conjugate was assessed by NIR laser 
irradiation at 980 nm and 1 W/cm² during different times. As a control, PBS and 
Waymouth media were also irradiated with the laser during the same durations. The final 
temperature of the tested suspensions and solutions were measured at the end of the NIR 
irradiation and are shown in Figure 6: 
 
Figure 6: Temperature elevation of different solutions and SWCNT-annexin V 




















Temperature elevation of different solutions 
and SWNT-annexin V conjugate suspension 
after NIR laser irradiation at room temperature
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The graph shows the increase in temperature (°C) of 1 mL of conjugate (100 mg/L), 
PBS or Waymouth medium as a function of irradiation time (min). Laser wavelength 
was 908 nm and power density 1.5 W/cm². One-way ANOVA was carried out on the 
R Studio software. (n = 2, *p<0.05 and **p<0.01). 
 
The SWCNT-anx V suspension showed a significantly higher temperature elevation at 
room temperature compared to PBS and Waymouth media. After 8 minutes of irradiation, 
temperature elevation reached a plateau at ΔT = 42.5°C on average while PBS and 
Waymouth media reached a plateau at ΔT = 17.8°C. These data suggest that the laser by 
itself induces a temperature elevation, but that the temperature elevation is significantly 
higher when the laser irradiation is combined with SWCNT-anx V conjugate. For 
example, after 1.5 minutes of treatment, the average temperature elevation of the wells 
filled with SWCNT was 16.9°C. For the same laser irradiation, the wells filled with PBS 
and Waymouth media presented a temperature elevation of 3.8°C. These results suggest 
that the conjugate generates a significant temperature elevation that can be used for our 
future experiments.  
3.2. In vitro PTT results of the SWCNT-annexin V conjugate 
 
As a scoping experiment, EMT6 cells were grown in 24 well plates and irradiated at 980 
nm, 1 W/cm² during different times at room temperature. The cells were incubated with 
the SWCNT-anx V conjugate prior to the NIR laser irradiation at room temperature to 
allow the conjugate to bind to the cells, and washed 4 times with PBS to remove excess 
conjugate. As a control, EMT6 cells incubated without conjugate were also irradiated. At 
the end of the NIR irradiation, an Alamar Blue Assay was performed to determine the 




Figure 7: Viability of EMT6 cells after NIR laser treatment at room temperature. 
The graph shows the relative cell viability of EMT6 cells incubated for 2 hours with 
the conjugate (in orange) or incubated with Waymouth medium as a control (in blue), 
prior to laser irradiation. After incubation with the conjugate, the cells were washed 
four times with PBS. Laser wavelength was 908 nm and power density 1.0 W/cm². 
One-way ANOVA was carried out on the R Studio software. (n = 2-3, *p<0.05 and 
**p<0.01).  
 
At room temperature, the treatment showed a significant drop in cell viability after 3 
minutes of irradiation. The control consisted of EMT6 cells irradiated with the laser in 
absence of SWCNT-anx V conjugate and did not present a trend of viability drop between 
1 to 7 minutes of laser irradiation. After 7 minutes of irradiation, the EMT6 cells 
incubated with the conjugate presented a viability of 17% on average. In this experiment, 
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of the cancer cells exposed to the conjugate while the laser alone had no effect on the cell 
viability. 
In a separate experiment, instead of measuring the cell viability at the end of the NIR 
irradiation at room temperature, the final temperature at the bottom of the well plate was 
measured using a type j thermocouple. This experiment makes it possible to determine 
the temperature rise induced by the PTT. The temperature rises resulting from the PTT 
are shown in Figure 8: 
 
Figure 8: Temperature elevation of EMT6 cells after NIR laser treatment at room 
temperature. The graph shows the temperature elevation (°C) of EMT6 cells 
incubated for 2 hours with the conjugate (in orange) or incubated with Waymouth 
medium as a control (in blue), prior to laser irradiation. After incubation with the 
conjugate, the cells were washed four times with PBS. Laser wavelength was 908 nm 
and power density 1.0 W/cm². One-way ANOVA was carried out on the R Studio 
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EMT6 cells treated with SWCNT-anx V conjugate and PTT showed an increased 
temperature elevation compared to the control treated with laser irradiation alone. These 
results suggest that the laser alone does not induce a strong rise in temperature, and that 
the combination of laser and conjugate is necessary to induce significant heat. 
The previous in vitro experiments were performed at room temperature and gave 
preliminary results on the effect of a PTT using the SWCNT-anx V conjugate on a TNBC 
model. However, one could argue that EMT6 cells may not react the same at room 
temperature as they do at a physiological temperature of 37 ° C. In order to determine if 
it is the case, a separate experiment was carried out at 37 ° C in an incubator. At the end 
of the NIR irradiation inside of the incubator, an Alamar Blue Assay was performed to 
determine the viability of the EMT6 cells, and the results are shown in Figure 9: 
 
Figure 9: Viability of EMT6 cells after NIR laser treatment at 37°C in an 
incubator. The graph shows the relative cell viability of EMT6 cells incubated for 2 
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(in blue), or incubated with nanotubes conjugated to the linker only (in green), prior to 
laser irradiation. After incubation with the conjugate, the cells were washed four times 
with PBS. Laser wavelength was 908 nm and power density 1.0 W/cm². One-way 
ANOVA was carried out on the R Studio software. (n = 3, *p<0.05 and **p<0.01). 
 
EMT6 cells treated with both SWCNT-anx V conjugate and laser irradiation showed a 
significant cell viability drop after 1 minute of irradiation. The cell viability drop reached 
a relative plateau after 3 minutes of laser irradiation at 14% cell viability on average. This 
result suggests that the optimal time of irradiation to treat EMT6 cells at 37°C is located 
between 2 and 3 minutes of laser irradiation.  
Comparatively, cells treated with laser alone, or SWNCT-linker (without Anx V) 
conjugate and laser did not result in a significant cell viability drop even after 7 minutes 
of laser irradiation. These results strongly suggest that Anx V is necessary for the 
conjugate to bind to the cells. After four washing steps, untargeted conjugate is washed 
away from the wells, and only the targeted conjugate induces a photothermal effect after 
laser irradiation in vitro at 37°C.  
In order to verify that the conjugate does not affect healthy cells, a separate experiment 
was performed using HUVEC cells as a model. HUVEC cells were grown in 24 wells 
plates until reaching confluency, and were then treated with laser irradiation alone at 
37°C, or laser irradiation at 37°C combined with SWCNT-anx V treatment. The results 




Figure 10: Viability of HUVEC cells after NIR laser treatment at 37°C in an 
incubator. The graph shows the temperature elevation (°C) of HUVEC cells incubated 
for two hours with the conjugate (in orange) or incubated with VCBM medium as a 
control (in blue), prior to laser irradiation. After incubation with the conjugate, the cells 
were washed four times with PBS. Laser wavelength was 908 nm and power density 
1.0 W/cm². One-way ANOVA was carried out on the R Studio software.  
(n = 3, *p<0.05 and **p<0.01). 
 
After 7 minutes of treatment, neither the group treated with SWCNT-anx V nor the group 
treated with laser irradiation alone showed a significant cell viability drop. In 
physiological conditions, healthy confluent endothelial cells do not express 
phosphatidylserine externally [53]. These results suggest that the SWCNT-anx V conjugate 
is not able to bind confluent healthy endothelial cells, and therefore, is not able to induce 
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3.3. In vivo PTT results of the SWCNT-annexin V conjugate in mice model 
Female BALB/cJ mice bearing EMT6 tumors were treated with intravenous injection of 
SWCNT-anx V in the lateral tail vein or intratumoral injections of the conjugate. The 
tumor was then treated by photothermal therapy. The temperature of the tumor was 
monitored during the laser irradiation using an IR camera. Seven days post photothermal 
therapy, the mice were euthanized, blood samples were gathered and centrifuged to 
collect the serum, and enzyme-linked immunosorbent assays were performed to quantify 
levels of TNFα in the serum. Mice treated with intravenous injections of SWCNT-anx V 
and photothermal therapy for 175 seconds presented significantly increased serum levels 
of TNFα (p<0.05). Mice treated with intratumoral injections of SWCNT-anx V combined 
with PTT for 175 seconds showed even more significant increased levels of TNFα in the 
serum compared to the control (p< 0.0001). Results are shown in Figure 11. 
 
Figure 11: TNFα concentrations in serum 24 hours after PTT in mice treated with 
IV injection or IT injection of the conjugate. The diagram shows the level of TNFα 




In a separate experiment, mice were treated with intratumoral injections of the conjugate 
combined with photothermal therapy until a final tumor temperature of 45, 50, 55 or 60°C 
was reached, and the concentration of four cytokines was measured in the serum 1 and 7 
days after PTT. The results are shown in Figure 12.  
Mice with final tumor temperatures of 45, 50 or 60°C showed significantly increased 
levels of TNFα in the serum 1 day after PTT compared to the control and increased levels 
of TNFα in the serum 7 days after PTT for tumor final temperatures of 45°C and 55°C. 
The treatment reaching a final temperature of 60°C also induced a significant release of 
IL-6 in the serum of the mice 1 day after PTT. The treatment did not induce increased 
levels of Il-12(p70) and IFNγ in the serum 1 day and 7 days after PTT, and the treatment 
did not induce increased levels of IL-6 in the serum 7 days after PTT. 
conjugate, or untreated mice as a control.  Laser wavelength was 908 nm and power 
density 1.0 W/cm². Blood samples were collected 24 hours after photothermal therapy. 
One-way ANOVA and Dunnett's multiple comparisons were carried out on the 




Figure 12: Cytokine concentrations in serum 1 day and 7 days after PTT with 
different final temperatures. The diagram shows the level of TNFα,  IL-6, IL-12(p70) 
and IFNγ in the serum of mice treated with IT injections of conjugate, or untreated 
mice as a control. Photothermal therapy was performed until reaching a final 
temperature of 45, 50, 55, or 60°C. Laser wavelength was 908 nm and power density 
1.0 W/cm². Blood samples were collected 1 day or 7 days after photothermal therapy. 
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For each treatment compared to the control, one-way ANOVA and Dunnett's multiple 
comparisons were carried out on the Graphpad Prism software version 9.0.  
(n = 4-5, *p<0.05, **p<0.01 and ***p<0.001) 
 
In recent work in our laboratory and following the same procedures, Patrick McKernan 
and Needa Virani treated BALB/cJ mice bearing EMT6 tumors with SWCNT-anx V and 
photothermal therapy [54]. This treatment was combined with administration of a 
checkpoint inhibitor; anti-CTLA-4, to the mice 8, 11, and 16 days post tumor inoculation. 
McKernan and Virani notably showed an increased survival of 55% in the group treated 
with both SWCNT-anx V photothermal therapy and anti-CTLA-4 at 100 days post tumor 
inoculation [53].  
Comparatively, no survival at 100 days was observed in the group treated with SWCNT-
anx V photothermal therapy alone, as well as in the group treated with anti-CTLA-4 alone 
[54]. In order to strengthen this pre-existing work and to highlight the abscopal effect 
induced by the treatment, we performed a quantification of proinflammatory cytokines 
present in the serum. BALB/cJ mice were treated following the same procedure, and 
separated in five groups (n = 5 in each group): 
1) Untreated control group (control).  
2) Mice treated with SWNT-Anx V injections, but not treated with photothermal 
therapy (SWNT). 
3) Mice treated with both SWNT-Anx V injections and photothermal therapy 
(SWNT+PTT). 
4) Mice treated with anti-CTLA-4 treatment alone (anti-CTLA-4). 
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5) Mice treated with SWNT-Anx V injections, photothermal therapy, and anti-
CTLA-4 (SWNT+PTT+anti-CTLA-4). 
Seven days post photothermal therapy, mice were euthanized, blood samples were 
taken and centrifugated to collect the serum, and enzyme-linked immunosorbent 
assays were performed to quantify serum levels of IFNγ, TNFα and IL6. A standard 
curve was performed for each cytokine to determine the concentration of IFNγ, TNFα 
and IL6 in the serum samples. These standard curves are available in Appendix C.   
Serum levels of IFNγ, TNFα and IL6 are shown in Figure 13: 
 
Figure 13: Cytokine concentrations in serum 7 days after PTT in mice treated 
with anti-CTLA4. The diagram shows the level of IFNγ, TNFα and IL-6 in the serum 
of mice treated with IT injections of conjugate, anti-CTLA-4 injection alone, IT 
injections of conjugate combined with PTT, IT injections of conjugate combined with 
PTT and anti-CTLA4 injection, or untreated mice as a control. Laser wavelength was 
908 nm and power density 1.0 W/cm² for 175 seconds. Blood samples were collected 
7 days after photothermal therapy. For each treatment compared to the control, one-
way ANOVA and Dunnett's multiple comparisons were carried out on the Graphpad 
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Prism software version 9.0.  
(n = 4-5, *p<0.05, and ****p<0.0001) 
 
Mice treated with anti-CTLA-4 alone or SWCNT-anx V injections alone did not give any 
significant increase of proinflammatory cytokines in the serum compared to the untreated 
control. Mice treated with the combination of SWCNT-anx V injections, photothermal 
therapy and anti-CTLA-4 injections gave significantly increased serum levels of IFNγ, 
TNFα and IL6 compared to the control, while mice treated with the combination of  
SWCNT-anx V injections and photothermal therapy gave significantly increased serum 
levels of TNFα compared to the control.  
An improvement in the overall health status of mice treated with targeted photothermal 
therapy coupled with injections of anti-CTLA-4 was observed within 7 days following 
photothermal therapy. During this post-treatment period, the mice treated with targeted 
photothermal therapy coupled with injections of anti-CTLA-4 moved around the entire 
cage, playing with the wooden cubes placed at their disposal. In comparison, mice in the 




Chapter 4: Discussion 
 
Triple negative breast cancer represents a strong clinical challenge due to the lack of 
targeted therapies [13-15]. An improved overall survival has been demonstrated in patients 
treated with radiation therapy in addition to chemotherapy and surgery [23-25], highlighting 
the importance of radiation therapy in the treatment of triple negative breast cancer.  
Our work proposes the use of annexin V conjugated to carbon nanotubes in a new 
approach of targeted photothermal therapy to answer this unmet clinical need. This new 
treatment has demonstrated in vitro efficacy on EMT6 cells, a very aggressive and highly 
metastatic model of triple negative breast cancer.  
Furthermore, it has been observed that annexin V is necessary for the effectiveness of the 
treatment. Indeed, the use of the conjugate without annexin V did not show any efficacy 
in vitro on an EMT6 model, suggesting that the treatment is specific and requires annexin 
V to bind to phosphatidylserine externalized by cancer cells. The treatment has also been 
shown to not induce cytotoxicity in a model of healthy endothelial cells. This information 
is crucial, because in the context of an intravenous injection of the conjugate, it is 
necessary that the treatment does not damage the endothelial cells of the vasculature. The 
experiments revealed that the conjugates do not appear to bind to endothelial cells, 
making the treatment specific to cancer cells externalizing phosphatidylserine. 
The increased levels of the four serum cytokines studied suggest that the treatment 
induces an antitumoral immune response. IFNγ is known for playing a key role in tumor 
surveillance, TNFα is a tumor associated macrophages activator, and IL-6 enhances 
lymphocyte and macrophage proliferation. The lowest temperature studied, 45°C, gave a 
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significantly higher level of TNFα at both 1 and 7 days after PTT compared to the 
untreated control (Figure 12). 
In recent works, Wang et al. were able to ablate a tumor reaching a final tumor 
temperature of 53°C using SWCNTs-based photothermal therapy [51]. Their experiments 
showed significantly increased levels of TNFα in serum 7 days after the treatment, similar 
to the results observed in our experiment. Using indocyanine green-based photothermal 
therapy, Chen et al. performed tumor ablation in mice and reached a final tumor 
temperature of 60°C [55]. Their experiments showed no significantly increased levels of 
IL-12 and IL-6 in serum 1 and 7 days after the treatment, which was similar to the results 
observed in our experiment. However, Chen et al. also measured the levels of IL-6 and 
IL-12 in serum 3 days after the treatment [56]. Significant increased levels of  
IL-12 and IL-6 in serum were measured, suggesting that the peak release of IL-12 and  
IL-6 is around 3 days after the treatment. Although our experiments showed a 
significantly increased level of IL-6 in serum 1 day after the treatment when reaching a 
tumor final temperature of 60°C, 3 days may be a more suitable time to quantify Il-6 and 
IL-12 release after photothermal therapy. 
The data on the effect of adding anti-CTLA-4 to PTT show that this resulted in 
significantly increased levels of cytokines IFNγ, TNFα and IL-6 compared to treatment 
with SWCNTs, anti-CTLA-4, or PTT alone (Figure 13). For these experiments, PTT was 
performed for 175 seconds, which we previously found to give a final tumor temperature 
of 54°C for EMT6 tumors in mice [54]. These data on cytokine release support the abscopal 
effect that we previously found, where a significant survival was obtained, as well as a 
significant increase in the relative numbers of cytotoxic and helper T cells, for the 
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combination of PTT and anti-CTLA-4 administration but no survival with anti-CTLA-4 
alone [54]. 
Chapter 5: Conclusions 
 
Annexin V was successfully conjugated to SWCNTs using a DSPE-PEG-MAL linker. 
The conjugate showed a photothermal effect, and the increase in temperature following 
photothermal therapy significantly reduced the cellular viability of EMT6 cells at room 
temperature as well as at 37 ° C. In the absence of annexin V, the conjugate was unable 
to induce significant cell death. This result suggests that the annexin V is indeed necessary 
for the use an SWNCTs conjugate for targeted photothermal therapy.  
The conjugate also demonstrated that it does not induce significant cell death after 
photothermal therapy on healthy endothelial HUVEC cells, suggesting that the conjugate 
is only able to bind to the cells externalizing the phosphatidylserine. In vivo experiments 
have demonstrated the ability of treatment to induce an increase in the level of 
proinflammatory cytokines in the mice bloodstream. These results support the hypothesis 
previously put forward that the treatment induces an abscopal effect, and that the 






For the study of the effect of tumor temperature on the release of cytokines, there was 
considerable variability in the data (Figure 12).  Cytokine research did not always increase 
as temperature increased.  Therefore, to reduce this variability, the number of animals per 
group should be increased, possibly doubling from n = 4-5 per group to n = 8-10 per 
group. 
In addition, it would be interesting to measure the release of IL-6 and IL-12 in the serum 
3 days after the photothermal therapy to be closer to the peak of release of these cytokines. 
The NIR laser light used for this treatment is rapidly attenuated by biological tissues, 
making the treatment of deep tumors more complicated. In order to address this problem, 
the conjugate could be activated using a radiofrequency generator. Indeed, 
radiofrequency fields are commonly used in biomedical imaging for their properties to 
penetrate biological tissues. In previous work in this lab, the conjugate has already 
demonstrated absorbance in a radiofrequency field with a frequency of 13.56MHz, and 
future work in this area could allow the development of a noninvasive targeted 
photothermal therapy based on radiofrequencies and an SWCNT-anx V conjugate. 
Furthermore, triple negative breast cancer was used as a model in this research, but this 
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Appendix A: Annexin V production and purification protocol 
______________________________________________________________________ 
Protocol from Charles Bagarie, source: Bagarie C. P., 2018. ‘Annexin a5 – 

























Appendix B: SWCNT-annexin V conjugation protocol 
______________________________________________________________________ 
Protocol from Dr. Patrick McKernan, source: McKernan, Patrick. 2018. ‘Therapeutic 




















































Figure a:IFNγ concentration Standard Curve





























Figure b: TNFα concentration Standard Curve





























Figure c: IL6 concentration Standard Curve 
